Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced a new publication in the Journal Thyroid. The First-in-Human Clinical feasibility study demonstrates the effectiveness of ablation of benign thyroid nodules using nsPFA energy. The study was designed to assess the ability of nsPFA energy to provide a safe and effective option for the trea
Related Questions
What are the potential competitive advantages or disadvantages of Pulse's nanosecond PFA technology compared to existing thyroid ablation methods and other companies' pipeline therapies?
How will the first-in-human efficacy and safety data for nsPFA in benign thyroid nodules influence Pulse Biosciences' valuation and revenue projections?
What regulatory milestones, reimbursement timelines, and market adoption risks should be considered when assessing the long-term impact of this publication on PLSE's stock performance?